No Data
No Data
Selected Announcement | Sino Biopharm's Class 1 innovative drug approved for new indications; LAKAI Pharmaceutical completes the placement of 17.636 million shares, raising approximately 0.23 billion Hong Kong dollars.
The innovative drug GLP-1R/GCGR dual agonist CMS-D005 from cms has received notification of clinical trial approval; Multiple Digital Intelligence is set to launch an IPO from November 28 to December 3, planning to globally issue 25.774 million shares.
Chengdu Expressway (01785): Chengwenqiong Expressway Company signed a land acquisition and demolition agreement for the Wenjiang District section with the Wenjiang District government.
Chengdu Expway (01785) announced that the Chengwenqiong Expway Company has signed an agreement with the Wenjiang District Government on November 27, 2024...
chengdu expway (01785): Chengwenqiong Expressway Company plans to enter into a land acquisition and demolition agreement with the People's Government of Wenjiang District.
Chengdu Expway (01785) has announced that the company will invest in the expansion project of the Chengdu-Wenchuan-Qionglai Expway...
CHENGDU EXPWAY: THIRD QUARTERLY RESULTS ANNOUNCEMENT FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024
Chengdu Expressway Invests 350 Million Yuan in Structured Deposit Product
chengdu expway (01785) to subscribe for structured deposits of 0.35 billion yuan.
Chengdu Expway (01785) announced that the company completed the acquisition of 0.35 billion yuan in RMB on October 14, 2024...